greeksoup/ stock research
Stock research / United States / HAE / FY2009

Haemonetics (HAE) FY2009 results: revenue $598 million

Haemonetics Corp. (HAE) reported revenue of $598 million for fiscal 2009, the year ended 28 March 2009. Net income was $59 million, and diluted earnings per share $1.14. The figures are the company's own, from the 10-K it filed with the SEC on 26 May 2011.

Revenue
$598 million
FY2009FY2009
Operating margin
14.3%
FY2009FY2009
Net income
$59 million
FY2009FY2009
Diluted EPS
$1.14
FY2009FY2009

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2009Last 8 years
Revenue598
Cost of revenue290
Gross profit308
Gross margin51.5%
Research and development23.9
Selling, general and administrative199
Operating income85.6
Operating margin14.3%
Interest expense0.1
Pre-tax income85.0
Income tax25.7
Effective tax rate30.2%
Net income59.3
Net margin9.9%
Diluted EPS$1.14
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2009Last 8 years
Operating cash flow116
Capital expenditure56.4
Free cash flow60.0
Free cash flow margin10.0%
Cash from investing-60.0
Cash from financing-30.7
Depreciation and amortisation36.5
Share-based compensation10.2
Buybacks60.0
Diluted shares, weighted52m

Balance sheet

$ millionFY2009Last 8 years
Shareholders' equity540
Cash and equivalents157

10-K for the year ended 28 March 2009, filed 26 May 2011: the filing.